Trials / Unknown
UnknownNCT05056116
A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer : a Phase Ⅱ Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase Ⅱ, open-label, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer.
Detailed description
A Phase 2, open-label, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Surufatinib Toripalimab | Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Toripalimab injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs. |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2022-06-01
- Completion
- 2024-06-01
- First posted
- 2021-09-24
- Last updated
- 2021-12-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05056116. Inclusion in this directory is not an endorsement.